Cara Therapeutics (Cara Therapeutics) Change In Receivables : $0.44 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Change In Receivables?

Cara Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $1.71 Mil. It means Cara Therapeutics's Accounts Receivable declined by $1.71 Mil from Sep. 2023 to Dec. 2023 .

Cara Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $0.44 Mil. It means Cara Therapeutics's Accounts Receivable declined by $0.44 Mil from Dec. 2022 to Dec. 2023 .

Cara Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $2.77 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cara Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 83.99.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cara Therapeutics's liquidation value for the three months ended in Dec. 2023 was $35.48 Mil.

Cara Therapeutics Change In Receivables Historical Data

The historical data trend for Cara Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Change In Receivables Chart

Cara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.20

-0.28

0.91

-3.30

0.44

Cara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															6.32	-2.81	-3.98	5.51	1.71

Cara Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44 Mil.

Cara Therapeutics (NAS:CARA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cara Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.765	/	3.004	*	91
=	83.99

2. In Ben Graham's calculation of liquidation value, Cara Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cara Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	100.758	-	68.759	+	0.75 * 2.765	+	0.5 * 2.821
=	35.48

Cara Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics (Cara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

69C:Germany 69C:Germany

Address

107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Executives

Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves	officer: Chief Medical Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion	officer: Sec'y; Chief Compliance & G.C.	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d.	officer: VP-Research & Development	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von	director	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum	director	675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard	officer: Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd	10 percent owner
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr	director
Thomas Charles Reilly	officer: Chief Financial Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd.	10 percent owner	RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027